RT Journal Article
SR Electronic
T1 Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.10.21267534
DO 10.1101/2021.12.10.21267534
A1 Wanwisa Dejnirattisai
A1 Robert H Shaw
A1 Piyada Supasa
A1 Chang Liu
A1 Arabella SV Stuart
A1 Andrew J Pollard
A1 Xinxue Liu
A1 Teresa Lambe
A1 Derrick Crook
A1 Dave I Stuart
A1 Juthathip Mongkolsapaya
A1 Jonathan S Nguyen-Van-Tam
A1 Matthew D Snape
A1 Gavin R Screaton
A1 the Com-COV2 study group
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.12.10.21267534.abstract
AB In this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant, compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post second-dose were obtained from participants in the Com-COV2 study who had received a two-dose COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines. There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT16b2 primary courses, with evidence of some recipients failing to neutralise at all. This will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection, although there is currently no evidence of increased potential to cause severe disease, hospitalization or death.Competing Interest StatementG.R.S sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM Vaccines. He receives no personal financial payment for this work. AJP reports grants from UKRI, CEPI and NIHR, during the conduct of the study. AJP is Chair of DHSCs Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in discussions on COVID19 vaccines, and is a member of the WHOs SAGE. The views expressed in this article are those of the authors and do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. The University of Oxford has entered into a partnership with AstraZeneca for the development of a coronavirus vaccine. JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed in this manuscript are those of its authors and not necessarily those of DHSC.Clinical Trial ISRCTN27841311 ISRCTN webpage: https://www.isrctn.com/ISRCTN27841311?q=27841311&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search Clinical Protocols https://comcovstudy.org.uk/study-protocol Funding StatementThe work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002) to DIS and GRS, DIS by the UKRI MRC (MR/N00065X/1). DIS and GRS are Jenner Investigators. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). Com-COV2 was funded by the UK Government through the National Institute for Health Research (NIHR), the Vaccine Task Force (VTF) and the Coalition for Epidemic Preparedness Innovations (CEPI). This research was supported by the NIHR Oxford Biomedical Research Centre, NIHR Guy's and St Thomas' Biomedical Research Centre, NIHR King's Clinical Research Facility and NIHR Policy Research Programme (PR-R17-0916-22001), the Southampton NIHR Biomedical Research Centre and Southampton NIHR Clinical Research Facility and delivered through the NIHR-funded National Immunisation Schedule Evaluation Consortium (NISEC). NVX-CoV2373 vaccine was supplied for use in Com-COV2 by Novavax, Inc. MDS and AJP are Jenner Investigators and NIHR Senior Investigators and supported by the Oxford NIHR Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South Central - Berkshire Research Ethics Committee gave ethical approval for this work. Reference 21/SC/0119.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon requests directed to the corresponding author, after approval of a proposal, data can be shared through a secure online platform.